Gracell Biotechnologies Inc Quick Ratio (GRCL) starting from the second quarter 2023 to second quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Gracell Biotechnologies Inc   (NASDAQ: GRCL)

Gracell Biotechnologies Inc 's Quick Ratio

GRCL's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Gracell Biotechnologies Inc 's Cash & cash equivalent, this led to improvement in Gracell Biotechnologies Inc 's Quick Ratio to 6.13, Quick Ratio remained below Gracell Biotechnologies Inc average.

Within Major Pharmaceutical Preparations industry 201 other companies have achieved higher Quick Ratio than Gracell Biotechnologies Inc in second quarter 2023. While Quick Ratio total ranking in the second quarter 2023 has deteriorated compared to the prior quarter from 602 to 621.

Explain Quick Ratio?
How much Cash & cash equivalents GRCL´s has?
What are GRCL´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GRCL Quick Ratio (Jun 30 2023)
Q4		 (Dec 31 2022)
Q3		 0
Q2		 0
Q1		 0
Q4
Y / Y Current Liabilities Change -16.45 % 35.84 % 31.42 % 95.29 % 31.42 %
Y / Y Cash & cash equivalent Change -22.51 % -26.48 % -26.48 % -11.36 % -26.48 %
Quick Ratio MRQ 6.13 4.48 6.61 5.36 6.61
GRCL's Total Ranking # 621 # 602 # 621 # #
Seq. Current Liabilities Change -43.32 % 47.41 % -32.71 % 48.6 % -7.85 %
Seq. Cash & cash equivalent Change -22.51 % 0 % -17.06 % 20.56 % -26.48 %



Quick Ratio second quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 202
Healthcare Sector # 327
Overall Market # 621


Quick Ratio Statistics
High Average Low
11.81 8.9 6.61
(Dec 31 2021)   (Dec 31 2022)




Financial Statements
Gracell Biotechnologies Inc 's Current Liabilities $ 27 Millions Visit GRCL's Balance sheet
Gracell Biotechnologies Inc 's Cash & cash equivalent $ 164 Millions Visit GRCL's Balance sheet
Source of GRCL's Sales Visit GRCL's Sales by Geography


Cumulative Gracell Biotechnologies Inc 's Quick Ratio

GRCL's Quick Ratio for the trailling 12 Months

GRCL Quick Ratio

 (Jun 30 2023)
12 Months		 (Dec 31 2022)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months
Y / Y Current Liabilities TTM Growth 32.95 % 47.27 % 53.94 % 63.12 % 54 %
Y / Y Cash & cash equivalent TTM Growth -21.65 % -22.7 % -1.62 % 28.24 % 67.05 %
Quick Ratio TTM 5.49 5.6 6.6 7.52 9.31
Total Ranking TTM # 4255 # 4218 # 3963 # #
Seq. Current Liabilities TTM Growth -3.32 % 8.51 % 5.52 % 20.1 % 7.1 %
Seq. Cash & cash equivalent TTM Growth -5.35 % -7.89 % -7.31 % -3.04 % -6.62 %

Quick ratio ranking by company, industry and sector >> Back to GRCL Financial Strength Comparisons >> Go to Compare GRCL Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in GRCL's Current Liabilities to $26.73 millions, cumulative Quick Ratio to 5.49 below the GRCL average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 564 other companies have achieved higher Quick Ratio than Gracell Biotechnologies Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2022 from 4218 to 4255.

Explain Quick Ratio?
How much Cash & cash equivalents GRCL´s has?
What are GRCL´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 565
Healthcare Sector # 1131
Within the Market # 4255


trailing twelve months Quick Ratio Statistics
High Average Low
11.81 9.42 6.61
(Dec 31 2021)   (Dec 31 2022)




Companies with similar Quick Ratio in the quarter ending Jun 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2023 MRQ Cash & cash equivalentJun 30 2023 MRQ Current Liabilities
Ventyx Biosciences Inc   16.58 $ 332.252  Millions$ 20.034  Millions
Cymabay Therapeutics Inc   16.38 $ 213.844  Millions$ 13.056  Millions
Pmv Pharmaceuticals Inc   16.34 $ 187.087  Millions$ 11.447  Millions
Mineralys Therapeutics Inc   16.29 $ 101.140  Millions$ 6.207  Millions
Tenax Therapeutics Inc   16.26 $ 13.394  Millions$ 0.824  Millions
Scpharmaceuticals Inc   16.16 $ 102.877  Millions$ 6.368  Millions
Lantern Pharma Inc   15.90 $ 47.949  Millions$ 3.016  Millions
Biomea Fusion Inc   15.53 $ 222.908  Millions$ 14.357  Millions
Pyxis Oncology Inc   15.46 $ 142.663  Millions$ 9.225  Millions
Nanoviricides inc   15.25 $ 8.150  Millions$ 0.534  Millions
Dynavax Technologies Corporation  15.19 $ 681.525  Millions$ 44.862  Millions
Landos Biopharma Inc   14.84 $ 44.736  Millions$ 3.015  Millions
Sensei Biotherapeutics Inc   14.72 $ 78.840  Millions$ 5.357  Millions
Eledon Pharmaceuticals Inc   14.57 $ 71.378  Millions$ 4.900  Millions
Larimar Therapeutics Inc   14.32 $ 104.200  Millions$ 7.275  Millions
Lipocine Inc   14.11 $ 25.790  Millions$ 1.827  Millions
Verve Therapeutics Inc   14.00 $ 462.476  Millions$ 33.031  Millions
Anixa Biosciences Inc   13.75 $ 25.534  Millions$ 1.857  Millions
Artelo Biosciences Inc   13.72 $ 8.272  Millions$ 0.603  Millions
Dianthus Therapeutics Inc   13.69 $ 55.240  Millions$ 4.034  Millions
Erasca Inc   13.62 $ 317.245  Millions$ 23.292  Millions
Syndax Pharmaceuticals Inc   13.46 $ 406.024  Millions$ 30.168  Millions
Annovis Bio Inc   13.41 $ 15.725  Millions$ 1.173  Millions
Rapt Therapeutics Inc   13.30 $ 204.998  Millions$ 15.414  Millions
Lisata Therapeutics Inc   13.23 $ 57.626  Millions$ 4.356  Millions
Protagonist Therapeutics inc   13.08 $ 313.401  Millions$ 23.952  Millions
Rani Therapeutics Holdings Inc   13.01 $ 74.606  Millions$ 5.735  Millions
Pasithea Therapeutics Corp   13.00 $ 26.770  Millions$ 2.059  Millions
Ataibeckley Inc   12.92 $ 227.492  Millions$ 17.604  Millions
Milestone Pharmaceuticals Inc   12.86 $ 87.591  Millions$ 6.809  Millions

Date modified: 2026-09-08T15:10:54+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.